Nurix Therapeutics, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Arthur T. Sands
- Full Time Employees
- 317
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1600 Sierra Point Parkway Brisbane CA United States of America 94005
- IPO Date
- Jul 24, 2020
- CIK
- 0001549595
- Website
- nurixtx.com
- Similar Companies
- Business
- Nurix Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics that modulate the ubiquitin proteasome system to treat human diseases. The company’s main products and services include research and development of targeted protein modulation therapies, primarily in oncology and immunology; proprietary E3 ligase-based drug discovery platforms; and pipeline assets such as clinical and preclinical drug candidates focused on various cancers and immune diseases. Nurix operates primarily in the United States, with its headquarters located in San Francisco, California, and it serves global markets through collaborations and partnerships. Founded in 2009, Nurix Therapeutics leverages its proprietary platform technologies to develop orally bioavailable small molecule drugs that degrade or inhibit proteins involved in disease pathways. Its core product categories encompass ubiquitin ligase modulators, molecular glues, and protein degraders designed to target otherwise undruggable proteins. In the last 1-2 years, Nurix has made significant strategic moves, including partnerships with major pharmaceutical companies for drug discovery collaboration, expansion of its clinical pipeline with the advancement of novel candidates into clinical trials, and increased investment in proprietary platform enhancements. The company has also focused on broadening its therapeutic areas and geographic reach through new licensing deals and research collaborations. These initiatives reflect Nurix’s strategy to accelerate the development of innovative therapies and expand its commercial potential. Nurix claims a strong position within the biotechnology industry, targeting oncology and immunology patient populations with unmet medical needs. It maintains several research collaborations and strategic alliances globally to further its drug discovery and development programs. The company remains independent, publicly traded under the ticker NRIX, and continues to build on its foundational science and robust pipeline capabilities.
Company News
Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement Pathways
Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates
Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences
Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer
842,089 Shares in Nurix Therapeutics, Inc. $NRIX Bought by Bank of America Corp DE
Nurix Therapeutics, Inc. (NRIX) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
Nurix Therapeutics, Inc. (NRIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Here's Why You Should Add NRIX Stock to Your Portfolio Now
Nurix Therapeutics, Inc. (NRIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Nurix Therapeutics (NRIX) Upgraded to Buy: Here's Why
Nurix Therapeutics to Participate in Upcoming September Investor Conferences
Nurix Therapeutics: Roche Has Changed The Economics Of The Bull Case
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
Nurix Therapeutics (NASDAQ:NRIX) Reaches New 1-Year High After Analyst Upgrade
Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Roche H1 Sales Decline on Currency Headwinds, Key Drugs Keep Momentum
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology